DGAP-Adhoc: Cytos Biotechnology Ltd announces change in Executive Board
Cytos Biotechnology AG / Key word(s): Change of Personnel
27.10.2014 18:00
Release of an ad hoc announcement pursuant to Art. 53 KR
---------------------------------------------------------------------------
Cytos Biotechnology Ltd announces change in Executive Board
Schlieren (Zurich), Switzerland, October 27, 2014 - Cytos Biotechnology
Ltd. (SIX:CYTN) ("Cytos" or the "Company") announced today that Mr.
Matthias Alder, Executive Vice President Corporate Development and Legal
Affairs, resigns from his function effective as of October 27, 2014.
The departure of Mr. Alder follows in the course of the winding down of key
operational activities of the Company. Mr. Alder has agreed to continue
his service to the Company as a consultant until February 28, 2015 to
complete ongoing projects and facilitate the transition of his
responsibilities.
For further information, please contact:
Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com
About Cytos Biotechnology Ltd
Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.
Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.
www.cytos.com
+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=IERDRGWDVW
Document title: Cchange in Executive Board
27.10.2014 News transmitted by EQS Schweiz AG.
The issuer is responsible for the contents of the release.
EQS publishes regulatory releases, media releases on the capital
market and press releases.
The EquityStory Group distributes authentic and real-time financial news
for over 1'300 listed companies.
The Swiss news archive can be found at www.equitystory.ch/news
---------------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Valor: -
Listed: Freiverkehr in Berlin, München, Stuttgart;
Frankfurt in Open Market ; SIX
End of Announcement EQS Group News-Service
---------------------------------------------------------------------------